-
Something wrong with this record ?
Small change - big consequence: The impact of C15-C16 double bond in a D‐ring of estrone on estrogen receptor activity
P. Vonka, L. Rarova, V. Bazgier, V. Tichy, T. Kolarova, J. Holcakova, K. Berka, M. Kvasnica, J. Oklestkova, E. Kudova, M. Strnad, R. Hrstka
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Estrogen Receptor alpha genetics metabolism MeSH
- Estradiol pharmacology therapeutic use MeSH
- Estrone * pharmacology MeSH
- Fulvestrant pharmacology therapeutic use MeSH
- Humans MeSH
- Cell Line, Tumor MeSH
- Breast Neoplasms * drug therapy metabolism MeSH
- Receptors, Estrogen metabolism MeSH
- Molecular Docking Simulation MeSH
- Tamoxifen pharmacology MeSH
- Check Tag
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Estrogen receptor alpha (ER) is a key biomarker for breast cancer, and the presence or absence of ER in breast and other hormone-dependent cancers decides treatment regimens and patient prognosis. ER is activated after ligand binding - typically by steroid. 2682 steroid compounds were used in a molecular docking study to identify novel ligands for ER and to predict compounds that may show anticancer activity. The effect of the most promising compounds was determined by a novel luciferase reporter assay. Two compounds, 7 and 12, showing ER inhibitory activity comparable to clinical inhibitors such as tamoxifen or fulvestrant were selected. We propose that the inhibitory effect of compounds 7 and 12 on ER is related to the presence of a double bond in their D-ring, which may protect against ER activation by reducing the electron density of the keto group, or may undergo metabolism leading to an active compound. Western blotting revealed that compound 12 decreased the level of ER in the breast cancer cell line MCF7, which was associated with reduced expression of both isoforms of the progesterone receptor, a well-known downstream target of ER. However, compound 12 has a different mechanism of action from fulvestrant. Furthermore, we found that compound 12 interferes with mitochondrial functions, probably by disrupting the electron transport chain, leading to induction of the intrinsic apoptotic pathway even in ER-negative breast cancer cells. In conclusion, the combination of computational and experimental methods shown here represents a rapid approach to determine the activity of compounds towards ER. Our data will not only contribute to research focused on the regulation of ER activity but may also be useful for the further development of novel steroid receptor-targeted drugs applicable in clinical practice.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23016125
- 003
- CZ-PrNML
- 005
- 20231026110352.0
- 007
- ta
- 008
- 231013s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jsbmb.2023.106365 $2 doi
- 035 __
- $a (PubMed)37468002
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Vonka, Petr $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Žlutý kopec 7, 656 53 Brno, Czech Republic; Laboratory of Growth Regulators, Faculty of Science of Palacký University & Institute of Experimental Botany of the Czech Academy of Sciences, Šlechtitelů 27, 783 71 Olomouc, Czech Republic
- 245 10
- $a Small change - big consequence: The impact of C15-C16 double bond in a D‐ring of estrone on estrogen receptor activity / $c P. Vonka, L. Rarova, V. Bazgier, V. Tichy, T. Kolarova, J. Holcakova, K. Berka, M. Kvasnica, J. Oklestkova, E. Kudova, M. Strnad, R. Hrstka
- 520 9_
- $a Estrogen receptor alpha (ER) is a key biomarker for breast cancer, and the presence or absence of ER in breast and other hormone-dependent cancers decides treatment regimens and patient prognosis. ER is activated after ligand binding - typically by steroid. 2682 steroid compounds were used in a molecular docking study to identify novel ligands for ER and to predict compounds that may show anticancer activity. The effect of the most promising compounds was determined by a novel luciferase reporter assay. Two compounds, 7 and 12, showing ER inhibitory activity comparable to clinical inhibitors such as tamoxifen or fulvestrant were selected. We propose that the inhibitory effect of compounds 7 and 12 on ER is related to the presence of a double bond in their D-ring, which may protect against ER activation by reducing the electron density of the keto group, or may undergo metabolism leading to an active compound. Western blotting revealed that compound 12 decreased the level of ER in the breast cancer cell line MCF7, which was associated with reduced expression of both isoforms of the progesterone receptor, a well-known downstream target of ER. However, compound 12 has a different mechanism of action from fulvestrant. Furthermore, we found that compound 12 interferes with mitochondrial functions, probably by disrupting the electron transport chain, leading to induction of the intrinsic apoptotic pathway even in ER-negative breast cancer cells. In conclusion, the combination of computational and experimental methods shown here represents a rapid approach to determine the activity of compounds towards ER. Our data will not only contribute to research focused on the regulation of ER activity but may also be useful for the further development of novel steroid receptor-targeted drugs applicable in clinical practice.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a fulvestrant $x farmakologie $x terapeutické užití $7 D000077267
- 650 12
- $a estron $x farmakologie $7 D004970
- 650 _2
- $a receptory pro estrogeny $x metabolismus $7 D011960
- 650 _2
- $a simulace molekulového dockingu $7 D062105
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 12
- $a nádory prsu $x farmakoterapie $x metabolismus $7 D001943
- 650 _2
- $a tamoxifen $x farmakologie $7 D013629
- 650 _2
- $a alfa receptor estrogenů $x genetika $x metabolismus $7 D047628
- 650 _2
- $a estradiol $x farmakologie $x terapeutické užití $7 D004958
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Rarova, Lucie $u Department of Experimental Biology, Faculty of Science, Palacký University Olomouc, Šlechtitelů 27, 78371 Olomouc, Czech Republic
- 700 1_
- $a Bazgier, Vaclav $u Department of Physical Chemistry, Faculty of Science, Palacký University Olomouc, třída 17. listopadu 12, 771 46 Olomouc, Czech Republic
- 700 1_
- $a Tichy, Vlastimil $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Žlutý kopec 7, 656 53 Brno, Czech Republic
- 700 1_
- $a Kolarova, Tamara $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Žlutý kopec 7, 656 53 Brno, Czech Republic
- 700 1_
- $a Holcakova, Jitka $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Žlutý kopec 7, 656 53 Brno, Czech Republic
- 700 1_
- $a Berka, Karel $u Department of Physical Chemistry, Faculty of Science, Palacký University Olomouc, třída 17. listopadu 12, 771 46 Olomouc, Czech Republic
- 700 1_
- $a Kvasnica, Miroslav $u Laboratory of Growth Regulators, Faculty of Science of Palacký University & Institute of Experimental Botany of the Czech Academy of Sciences, Šlechtitelů 27, 783 71 Olomouc, Czech Republic
- 700 1_
- $a Oklestkova, Jana $u Laboratory of Growth Regulators, Faculty of Science of Palacký University & Institute of Experimental Botany of the Czech Academy of Sciences, Šlechtitelů 27, 783 71 Olomouc, Czech Republic
- 700 1_
- $a Kudova, Eva $u Institute of Organic Chemistry and Biochemistry AS CR, Flemingovo náměstí 2, 166 10, Praha 6, Czech Republic
- 700 1_
- $a Strnad, Miroslav $u Laboratory of Growth Regulators, Faculty of Science of Palacký University & Institute of Experimental Botany of the Czech Academy of Sciences, Šlechtitelů 27, 783 71 Olomouc, Czech Republic
- 700 1_
- $a Hrstka, Roman $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Žlutý kopec 7, 656 53 Brno, Czech Republic; Laboratory of Growth Regulators, Faculty of Science of Palacký University & Institute of Experimental Botany of the Czech Academy of Sciences, Šlechtitelů 27, 783 71 Olomouc, Czech Republic. Electronic address: hrstka@mou.cz
- 773 0_
- $w MED00004950 $t The Journal of steroid biochemistry and molecular biology $x 1879-1220 $g Roč. 233, č. - (2023), s. 106365
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37468002 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20231013 $b ABA008
- 991 __
- $a 20231026110345 $b ABA008
- 999 __
- $a ok $b bmc $g 1999942 $s 1202487
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 233 $c - $d 106365 $e 20230717 $i 1879-1220 $m Journal of steroid biochemistry and molecular biology $n J Steroid Biochem Mol Biol $x MED00004950
- LZP __
- $a Pubmed-20231013